320 related articles for article (PubMed ID: 30312651)
1. Glucagon-like peptides-1 from phylogenetically ancient fish show potent anti-diabetic activities by acting as dual GLP1R and GCGR agonists.
Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
Mol Cell Endocrinol; 2019 Jan; 480():54-64. PubMed ID: 30312651
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-related peptides from phylogenetically ancient fish reveal new approaches to the development of dual GCGR and GLP1R agonists for type 2 diabetes therapy.
Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
Peptides; 2018 Dec; 110():19-29. PubMed ID: 30391422
[TBL] [Abstract][Full Text] [Related]
3. Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities.
Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
Eur J Pharmacol; 2020 Jul; 878():173101. PubMed ID: 32320703
[TBL] [Abstract][Full Text] [Related]
4. A long-acting, dual-agonist analogue of lamprey GLP-1 shows potent insulinotropic, β-cell protective, and anorexic activities and improves glucose homeostasis in high fat-fed mice.
Graham GV; McCloskey A; Abdel-Wahab YH; Conlon JM; Flatt PR
Mol Cell Endocrinol; 2020 Jan; 499():110584. PubMed ID: 31539596
[TBL] [Abstract][Full Text] [Related]
5. Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A review.
Conlon JM; O'Harte FPM; Flatt PR
Peptides; 2022 Jan; 147():170706. PubMed ID: 34861327
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.
Graham GV; Conlon JM; Abdel-Wahab YH; Gault VA; Flatt PR
Peptides; 2018 Feb; 100():182-189. PubMed ID: 29157578
[TBL] [Abstract][Full Text] [Related]
7. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
Mol Cell Endocrinol; 2016 Aug; 431():133-44. PubMed ID: 27179756
[TBL] [Abstract][Full Text] [Related]
8. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
[TBL] [Abstract][Full Text] [Related]
9. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
[TBL] [Abstract][Full Text] [Related]
11. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
12. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
13. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
Bhat VK; Kerr BD; Flatt PR; Gault VA
Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
[TBL] [Abstract][Full Text] [Related]
14. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
Gault VA; Bhat VK; Irwin N; Flatt PR
J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
[TBL] [Abstract][Full Text] [Related]
15. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.
Day JW; Gelfanov V; Smiley D; Carrington PE; Eiermann G; Chicchi G; Erion MD; Gidda J; Thornberry NA; Tschöp MH; Marsh DJ; SinhaRoy R; DiMarchi R; Pocai A
Biopolymers; 2012; 98(5):443-50. PubMed ID: 23203689
[TBL] [Abstract][Full Text] [Related]
16. Development and characterisation of a novel glucagon like peptide-1 receptor antibody.
Biggs EK; Liang L; Naylor J; Madalli S; Collier R; Coghlan MP; Baker DJ; Hornigold DC; Ravn P; Reimann F; Gribble FM
Diabetologia; 2018 Mar; 61(3):711-721. PubMed ID: 29119245
[TBL] [Abstract][Full Text] [Related]
17. Glucagon Acting at the GLP-1 Receptor Contributes to β-Cell Regeneration Induced by Glucagon Receptor Antagonism in Diabetic Mice.
Wei T; Cui X; Jiang Y; Wang K; Wang D; Li F; Lin X; Gu L; Yang K; Yang J; Hong T; Wei R
Diabetes; 2023 May; 72(5):599-610. PubMed ID: 36826938
[TBL] [Abstract][Full Text] [Related]
18. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
19. Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis.
Ali S; Lamont BJ; Charron MJ; Drucker DJ
J Clin Invest; 2011 May; 121(5):1917-29. PubMed ID: 21540554
[TBL] [Abstract][Full Text] [Related]
20. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
Thomas L; Martel E; Rist W; Uphues I; Hamprecht D; Neubauer H; Augustin R
Diabetes Obes Metab; 2024 Jun; 26(6):2368-2378. PubMed ID: 38560764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
